LNTH:NSD-Lantheus Holdings Inc. (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | NASDAQ Global Market

Last Closing

USD 65.56

Change

+0.36 (+0.55)%

Market Cap

USD 0.33B

Volume

0.58M

Analyst Target

USD 21.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Lantheus Holdings Inc is engaged in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products. These products assist clinicians in the diagnosis of cardiovascular and other diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
NBIX Neurocrine Biosciences Inc

-4.17 (-2.91%)

USD 13.68B
VTRS Viatris Inc

+0.09 (+0.77%)

USD 13.36B
ITCI Intracellular Th

-4.21 (-5.91%)

USD 7.72B
ALKS Alkermes Plc

-0.49 (-1.99%)

USD 4.08B
ALVO Alvotech

-0.32 (-2.31%)

USD 3.87B
AVDL Avadel Pharmaceuticals PLC

-1.93 (-10.62%)

USD 3.39B
HCM HUTCHMED DRC

+0.02 (+0.10%)

USD 3.23B
INDV Indivior PLC Ordinary Shares

+0.08 (+0.45%)

USD 2.93B
EVO Evotec SE ADR

+0.05 (+0.97%)

USD 2.51B
AMPH Amphastar P

-0.56 (-1.31%)

USD 2.09B

ETFs Containing LNTH

MEDI Harbor Health Care ETF 2.94 % 0.00 %

-0.55 (0%)

USD 0.01B
QWST 1.37 % 0.00 %

N/A

N/A
WELP:LSE HAN-GINS Indxx Healthcare.. 1.33 % 0.00 %

-3.95 (0%)

USD 0.02B
GVLU Tidal ETF Trust 0.51 % 0.00 %

+0.01 (+0%)

USD 0.16B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.74% 67% D+ 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.74% 67% D+ 71% C-
Trailing 12 Months  
Capital Gain -23.28% 52% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.28% 52% F 31% F
Trailing 5 Years  
Capital Gain 160.47% 96% N/A 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 160.47% 96% N/A 90% A-
Average Annual (5 Year Horizon)  
Capital Gain 56.18% 89% A- 92% A
Dividend Return 56.18% 89% A- 91% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 77.41% 33% F 21% F
Risk Adjusted Return 72.57% 96% N/A 91% A-
Market Capitalization 0.33B 95% A 87% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 9.70 58% 61%
Price/Book Ratio 4.93 23% 23%
Price / Cash Flow Ratio 13.25 10% 20%
Price/Free Cash Flow Ratio 8.00 24% 30%
Management Effectiveness  
Return on Equity 51.73% 97% 97%
Return on Invested Capital 23.52% 91% 90%
Return on Assets 20.89% 96% 99%
Debt to Equity Ratio 68.84% 28% 33%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.